Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Active, not recruiting · NCT03333343 · Registry updated 2026-01-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | EGFR-mutant Non-small Cell Lung Cancer | Active, not recruiting | Phase 1 | 2026-01-16 | NCT03333343 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||